Publications:58
- Home
- Profiles
Video Visit Available
Accepting New Patients
Mount Sinai Doctors
Video Visit Available
Accepting New PatientsMax W Sung, MD
Cancer (Oncology), Hematology-Oncology, Internal Medicine
No Patient Experience Ratings
Ruttenberg Treatment Center
212-241-6756
- About Me
- Clinical Focus
- Education & Certifications
- Research
- Locations
- Insurance
- Publications
- Industry Relationships
About Me
Max Sung, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He has been on the faculty at Mount Sinai since 1987.
Dr. Sung specializes in gastrointestinal cancers including liver, bile duct, pancreas, esophagus, stomach, colon/rectum, and anus cancers. His approach to cancer treatment is multi-disciplinary, and involves collaboration with other specialties such as surgery, interventional radiology, and radiation therapy.
Dr. Sung has held numerous leadership roles at Mount Sinai, including Medical Director of The Ruttenberg Treatment Center and Chair of the Data and Safety Monitoring Committee for cancer clinical trials.
Dr. Sung is involved in clinical cancer research and has authored numerous peer-reviewed publications on innovative and translational treatments.
Dr. Sung is fluent in English and Chinese (Cantonese and Mandarin), and has a working knowledge of German and French.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai West
About Me
Max Sung, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He has been on the faculty at Mount Sinai since 1987.
Dr. Sung specializes in gastrointestinal cancers including liver, bile duct, pancreas, esophagus, stomach, colon/rectum, and anus cancers. His approach to cancer treatment is multi-disciplinary, and involves collaboration with other specialties such as surgery, interventional radiology, and radiation therapy.
Dr. Sung has held numerous leadership roles at Mount Sinai, including Medical Director of The Ruttenberg Treatment Center and Chair of the Data and Safety Monitoring Committee for cancer clinical trials.
Dr. Sung is involved in clinical cancer research and has authored numerous peer-reviewed publications on innovative and translational treatments.
Dr. Sung is fluent in English and Chinese (Cantonese and Mandarin), and has a working knowledge of German and French.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai West
About Me
Max Sung, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He has been on the faculty at Mount Sinai since 1987.
Dr. Sung specializes in gastrointestinal cancers including liver, bile duct, pancreas, esophagus, stomach, colon/rectum, and anus cancers. His approach to cancer treatment is multi-disciplinary, and involves collaboration with other specialties such as surgery, interventional radiology, and radiation therapy.
Dr. Sung has held numerous leadership roles at Mount Sinai, including Medical Director of The Ruttenberg Treatment Center and Chair of the Data and Safety Monitoring Committee for cancer clinical trials.
Dr. Sung is involved in clinical cancer research and has authored numerous peer-reviewed publications on innovative and translational treatments.
Dr. Sung is fluent in English and Chinese (Cantonese and Mandarin), and has a working knowledge of German and French.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai West
Clinical Focus
- Chemotherapy
- Colon Cancer
- Colorectal Cancer
- Esophageal Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach Cancer
- Chemotherapy
- Colon Cancer
- Colorectal Cancer
- Esophageal Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach Cancer
Education
MD, Yeshiva University Albert Einstein College of Medicine
Internship, Internal Medicine
Montefiore Medical Center
Residency, Internal Medicine
Montefiore Medical Center
Fellowship, Hematology
Montefiore Medical Center
Certifications
Medical Oncology
American Board of Internal Medicine
Research
Dr. Sung is currently conducting clinical trials of immunotherapy in patients with advanced colorectal and breast cancers using gene transfer therapy. He is also involved in clinical trials of suicide gene therapy and differentiation therapies for colorectal cancer, and anti-angiogenesis therapy for hepatocellular carcinoma.
Dr. Sung actively participates in multi-modality treatment approaches (surgery/radiation/chemotherapy) to cancers of the liver, colon-rectum, carcinoid, pancreas, esophagus, stomach and anal cancers, and is also experienced in regional treatment modalities such as hepatic arterial chemotherapy/chemoembolization and intraperitoneal chemotherapy.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Cigna - Medicare
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Arvind Dasari, Erika P. Hamilton, Gerald S. Falchook, Judy S. Wang, Daneng Li, Max W. Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Scott Paulson. Investigational New Drugs
- Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Philipp K. Haber, Florian Castet, Miguel Torres-Martin, Carmen Andreu-Oller, Marc Puigvehí, Maeda Miho, Pompilia Radu, Jean Francois Dufour, Chris Verslype, Carolin Zimpel, Jens U. Marquardt, Peter R. Galle, Arndt Vogel, Melanie Bathon, Tim Meyer, Ismail Labgaa, Antonia Digklia, Lewis R. Roberts, Mohamed A. Mohamed Ali, Beatriz Mínguez, Davide Citterio, Vincenzo Mazzaferro, Fabian Finkelmeier, Jörg Trojan, Burcin Özdirik, Tobias Müller, Moritz Schmelzle, Anthony Bejjani, Max W. Sung, Myron E. Schwartz, Richard S. Finn, Swan Thung, Augusto Villanueva, Daniela Sia, Josep M. Llovet. Gastroenterology
- Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. Brett Marinelli, Edward Kim, Antonio D'Alessio, Mario Cedillo, Ishan Sinha, Neha Debnath, Masatoshi Kudo, Naoshi Nishida, Anwaar Saeed, Hannah Hildebrand, Ahmed O. Kaseb, Yehia I. Abugabal, Anjana Pillai, Yi Hsiang Huang, Uqba Khan, Mahvish Muzaffar, Abdul Rafeh Naqash, Rahul Patel, Aaron Fischman, Vivian Bishay, Dominik Bettinger, Max Sung, Celina Ang, Myron Schwartz, David J. Pinato, Thomas Marron. Journal for ImmunoTherapy of Cancer
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Sung did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.